What Is TFC-1067?

TFC-1067, Sirona’s patented drug, outperforms current market actives while remaining safe and hydroquinone-free. The compound has undergone comprehensive clinical and preclinical testing, including a double-blind analysis for dyschromia in the United States and a new trial in the European Union for a higher dose. Clinical studies have shown that the compound outperforms hydroquinone in treating dyschromia while having no side effects.

Rodan + Fields is a cosmetics company based in California.

Rodan + Fields was founded in 2002 by Stanford-trained dermatologists Dr Katie Rodan and Dr Kathy Fields to provide customers with the best skin of their lives. The Doctors’ understanding that healthy skin empowers people to feel positively inspired by the creation of the brand. Rodan + Fields, founded in the digital age and built to meet consumers where they live and shop through mobile and social networks, disrupt the industry with its regimen-based skincare and powerful Independent Consultant group.

Please visit www.rodanandfields.com for more information.

Sirona Biochem Corp. is an acronym for Sirona Biochem Corporation.

TFC-1067, Sirona’s proprietary compound, is a cosmetic ingredient and drug development firm with its own platform technology. Sirona specialises in carbohydrate molecule stabilisation to increase efficacy and safety. To maximise sales potential, new substances are patented.

Sirona’s compounds are licenced to leading companies worldwide to exchange licencing fees, milestone fees, and continuing royalties. TFChem, Sirona’s laboratory in France, has received several French national science awards and European Union and French government grants. Please visit www.sironabiochem.com for more information.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as specified in the TSX Venture Exchange) accept responsibility for this publication’s sufficiency or accuracy.